Currently out of the existing stock ratings of Kalpit Patel, 68 are a BUY (70.1%), 29 are a HOLD (29.9%).

Kalpit Patel

Work Performance Price Targets & Ratings Chart

Analyst Kalpit Patel, currently employed at B. RILEY, carries an average stock price target met ratio of 38.15% that have a potential upside of 63.6% achieved within 135 days.

Kalpit Patel’s has documented 192 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BCYC, Bicycle Therapeutics Ltd at 02-May-2025.

Wall Street Analyst Kalpit Patel

Analyst best performing recommendations are on GERN (GERON).
The best stock recommendation documented was for GERN (GERON) at 2/27/2025. The price target of $2 was fulfilled within 1 day with a profit of $0.37 (15.61%) receiving and performance score of 156.12.

Average potential price target upside

of $9.73 (50.96%) on LBPH (LONGBOARD PHARMACEUTICALS).
of $8.47 (22.05%) on MRTX (MIRATI THER).
of $7.62 (47.96%) on XFOR (X4 PHARMACEUTICALS).

BCYC Bicycle Therapeutics Ltd INFI Infinity Pharmaceuticals INKT Mink Therapeutics KYMR Kymera Therapeutics MGTA Magenta Therapeutics RIGL Rigel Pharmaceuticals FBRX Forte Biosciences ALLO Allogene Therapeutics ENTX Entera Bio Ltd INAB In8bio VINC Vincerx Pharma MRTX Mirati Ther DERM Journey Medical Corp GERN Geron VRDN Viridian Therapeutics SNDX Syndax Pharmaceuticals LBPH Longboard Pharmaceuticals CRBP Corbus Pharmaceuticals PDSB PDS Biotechnology Corp VSTM Verastem XFOR X4 Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jeffrey Hung (MORGAN STANLEY)